Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics.[1]
 | |
| Company type | Public |
|---|---|
| Expert Market: NPTX | |
| Industry | Pharmaceutical Biotechnology |
| Founders | Dean Petkanas, Thoma Kikis |
| Headquarters | Doylestown, Pennsylvania |
| Total assets | Patents US 9611213, US 10004722 |
| Website | neuropathix.com |
In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019[2][3][4] along with other therapeutic agents that prevent neuropathic pain, mitochondrial dysfunction, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol.[5] Neuropathix family of monotherapeutic small molecules are focused on treating oxidative stress-related diseases, inflammation, chronic pain management and neurodegenerative disorders.
In late 2021, Neuropathix subsidiary Kannalife, was awarded a non-dilutive three-year $2.97 Million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institutes of Health (NIH).[6] The three-year study grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for enhanced pain management and provides funding specifically in the Development of KLS-13019 for Neuropathic Pain.[7]
Neuropathix is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County to treat Chemotherapy-induced peripheral neuropathy, Hepatic encephalopathy, Mild Traumatic Brain Injury and CTE.[8]
References edit
- ^ Rees, Victoria (November 26, 2020). "Cannabinoid series: a CBD-inspired molecule to increase bioavailability". European Pharmaceutical Review. Retrieved 2020-11-26.
- ^ Kinney WA, McDonnell ME, Zhong HM, Liu C, Yang L, Ling W, Qian T, Chen Y, Cai Z, Petkanas D, et al. (April 2016). "Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability". ACS Medicinal Chemistry Letters. 7 (4): 424–8. doi:10.1021/acsmedchemlett.6b00009. PMC 4834656. PMID 27096053.
- ^ Brenneman DE, Petkanas D, Kinney WA (September 2018). "Pharmacological Comparisons Between Cannabidiol and KLS-13019". Journal of Molecular Neuroscience. 66 (1): 121–134. doi:10.1007/s12031-018-1154-7. PMC 6150782. PMID 30109468.
- ^ Brenneman DE, Kinney WA, Ward SJ (August 2019). "Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity". Journal of Molecular Neuroscience. 68 (4): 603–619. doi:10.1007/s12031-019-01321-z. PMC 6615992. PMID 31077084.
- ^ Foss JD, Farkas DJ, Huynh LM, Kinney WA, Brenneman DE, Ward SJ (April 2021). "Behavioral and pharmacological effects of cannabidiol (CBD) and the CBD analogue KLS‐13019 in mouse models of pain and reinforcement". British Journal of Pharmacology. 178 (15): 3067–3078. doi:10.1111/bph.15486. PMID 33822373. S2CID 233035597.
- ^ "Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)". finance.yahoo.com. Retrieved 2021-09-28.
- ^ "Development of KLS-13019 for Neuropathic Pain". reporter.nih.gov. Retrieved 2021-09-28.
- ^ Baskin, Ben (July 12, 2016). "How cannabis is helping one company research treatment of CTE". Sports Illustrated. Retrieved 2016-07-12.